Genmab (Otc) (GMAB) has released an update.
Genmab’s TIVDAK has received full FDA approval for treating patients with recurrent or metastatic cervical cancer after showing an overall survival benefit in a Phase 3 study. TIVDAK is the first antibody-drug conjugate for this patient group that has demonstrated positive survival data compared to chemotherapy. This approval marks a significant advancement for women with advanced cervical cancer, offering a new treatment option where limited options existed before.
For further insights into GMAB stock, check out TipRanks’ Stock Analysis page.
